Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients
暂无分享,去创建一个
F. Hodi | N. Ibrahim | P. Ott | J. Weinberg | J. Luke | M. Marmarelis | Marlene Garcia-Neuer | Meredith E. Davis | N. Bailey | E. Buchbinder | Hilary Donahue | S. Jangi | Nageatte Ibrahim
[1] L. Molinero,et al. The composition of the microbiota modulates allograft rejection. , 2016, The Journal of clinical investigation.
[2] C. Huttenhower,et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis , 2016, Nature Communications.
[3] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[4] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[5] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[6] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[7] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[8] J. Kench,et al. Ipilimumab‐induced toxicities and the gastroenterologist , 2015, Journal of gastroenterology and hepatology.
[9] D. Schadendorf,et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Kirkwood,et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. , 2014, JAMA.
[11] F. Hodi,et al. Ipilimumab and its toxicities: a multidisciplinary approach. , 2013, The oncologist.
[12] A. Shinagare,et al. Ipilimumab-associated colitis: CT findings. , 2013, AJR. American journal of roentgenology.
[13] A. Hauschild,et al. Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[15] M. Kagnoff,et al. GM-CSF: a role in immune and inflammatory reactions in the intestine , 2010, Expert review of gastroenterology & hepatology.
[16] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[17] Jing Jing Li,et al. A randomized, controlled trial of early versus late initiation of dialysis. , 2010, The New England journal of medicine.
[18] H. Pehamberger,et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] P. Brigidi,et al. Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians , 2010, PloS one.
[20] G. Triadafilopoulos,et al. Risk of perforation from a colonoscopy in adults: a large population-based study. , 2009, Gastrointestinal endoscopy.
[21] N. Hunt,et al. The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation , 2008, Cell Research.
[22] J. Morley. The aging gut: physiology. , 2007, Clinics in geriatric medicine.
[23] Y. Belkaid,et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β– and retinoic acid–dependent mechanism , 2007, The Journal of experimental medicine.
[24] J. Belaiche,et al. Noninvasive Assessment of Crohn's Disease Intestinal Lesions with 18F-FDG PET/CT , 2007, Journal of Nuclear Medicine.
[25] A. Feldman,et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Targan,et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. , 2010, Cancer immunity.
[27] M. Gordon. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 , 2008 .